Central Nervous System (CNS) Therapeutics Market Report 2024 by Delvens offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Central Nervous System (CNS) Therapeutics market size was estimated at USD 104.70 billion in 2023 and is projected to reach USD 159.84 billion in 2030 at a CAGR of 6.23% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/central-nervous-system-therapeutics-market
The prominent players in the Central Nervous System (CNS) Therapeutics market are
· Biogen
· Otsuka Pharmaceutical Co. Ltd
· Eli Lilly and Company
· Merck KGaA
· AstraZeneca
· Takeda Pharmaceutical Company Limited
· Novartis AG
· Teva Pharmaceutical Industries Ltd
· Johnson & Johnson Private Limited
· Pfizer Inc.
· GlaxoSmithKline PLC
· Shire PLC
· Cipla Inc.
· Lupin Ltd
· Glenmark Pharmaceuticals
· AbbVie Inc.
· BIAL Group
· Bristol-Myers Squibb
· Allergan Plc
· Alkermes Plc and More
Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. The CNS includes the brain and spinal cord and plays a crucial role in controlling various bodily functions and behaviours. CNS therapeutics are used to treat a wide range of neurological and psychiatric conditions.
Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc. CNS therapeutics play a crucial role in improving the quality of individuals with various neurological and psychiatric conditions.
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/central-nervous-system-therapeutics-market
Regional Analysis
North America to Dominate the Market
· North America is estimated to account for the largest market share during the forecast period. The increased usage of technology in the healthcare sector in the United States, along with the increasing product launches, owing to the rising burden of the central nervous system disease, and the rising level of research and development are driving the growth of the market.
· Moreover, the rising burden of neurodegenerative diseases such as Alzheimer’s within the region is expected to contribute to the market growth during the forecast period.
Key Findings
· The market is bifurcated based on disease into neurovascular diseases, trauma, mental health, degenerative disease, infectious diseases, cancer, and others. The degenerative disease is expected to dominate the market in this segment. This growth can be attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis. In addition to this, the rise in drug development pipeline, and the potential of this segment open opportunities for clinical studies, product launches, and strategic collaborations is further expected to drive the market during the forecast period.
· Based on drug class, the market is segmented into analgesics, antidepressants, anaesthetics, anti-Parkinson drugs, anti-epileptics, and other drug classes. The antidepressants segment led the CNS therapeutics market in this segment and is expected to dominate the market during the forecast period due to increasing prevalence of depression and the rising demand for effective treatments.
· Based on distribution channel, the market can be segmented into hospital-based pharmacies, retail-based pharmacies and online pharmacies. The hospital-based pharmacies dominated the market in this segment due to rapid increase in prevalence of CNS diseases in geriatric population, technological advancements and lifestyle changes.
· By age group, the market is segmented into paediatric, adult and geriatric. The geriatric population dominated the market in this segment and is expected to dominate the market during the forecast period. This is due to the rapid increase in CNS diseases such as Alzheimer’s in the geriatric population.
· The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, increased usage of technology in the health care sector along with the increasing product launches, owing to the rising burden of CNS disease and the rising level of research and development are driving the growth of the market.
Access Full Report: https://www.delvens.com/report/central-nervous-system-therapeutics-market
In addition to the market data for the Central Nervous System (CNS) Therapeutics Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
More Related Reports:
Immunohistochemistry (IHC) Market
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
